Listeria monocytogenes cancer vaccines: bridging innate and adaptive immunity.

IF 3.1 Q2 MICROBIOLOGY

Current Clinical Microbiology Reports Pub Date : 2019-12-01 Epub Date: 2019-11-20 DOI:10.1007/s40588-019-00133-4

Zachary T Morrow, Zachary M Powers, John-Demian Sauer

{"title":"Listeria monocytogenes cancer vaccines: bridging innate and adaptive immunity.","authors":"Zachary T Morrow, Zachary M Powers, John-Demian Sauer","doi":"10.1007/s40588-019-00133-4","DOIUrl":null,"url":null,"abstract":"Purpose of the review: Immunotherapy has emerged as a promising cancer treatment, however success in only select clinical indications underscores the need for novel approaches. Recently Listeria monocytogenes-based vaccines have been developed to drive tumor specific T-cell responses. Here, we discuss recent preclinical studies using L. monocytogenes vaccines, innate immune pathways that influence T-cell priming, and new vaccine strategies in clinical trials.Recent findings: Recent studies indicate that in addition to inducing antigen specific T-cell responses, L. monocytogenes vaccines remodel the TME. In addition, several innate immune pathways influence adaptive immune responses to L. monocytogenes and modulating these pathways holds promise to enhance anti-tumor T-cell responses.Summary: The interplay between innate and adaptive immune responses to L. monocytogenes is poorly understood. Understanding these interactions will facilitate the design of better anti-cancer vaccines and improved use of combination therapies.","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"6 4","pages":"213-224"},"PeriodicalIF":3.1000,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40588-019-00133-4","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Clinical Microbiology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40588-019-00133-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/11/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 12

Abstract

Purpose of the review: Immunotherapy has emerged as a promising cancer treatment, however success in only select clinical indications underscores the need for novel approaches. Recently Listeria monocytogenes-based vaccines have been developed to drive tumor specific T-cell responses. Here, we discuss recent preclinical studies using L. monocytogenes vaccines, innate immune pathways that influence T-cell priming, and new vaccine strategies in clinical trials.

Recent findings: Recent studies indicate that in addition to inducing antigen specific T-cell responses, L. monocytogenes vaccines remodel the TME. In addition, several innate immune pathways influence adaptive immune responses to L. monocytogenes and modulating these pathways holds promise to enhance anti-tumor T-cell responses.

Summary: The interplay between innate and adaptive immune responses to L. monocytogenes is poorly understood. Understanding these interactions will facilitate the design of better anti-cancer vaccines and improved use of combination therapies.

查看原文本刊更多论文

单核细胞增生李斯特菌癌症疫苗:桥接先天免疫和适应性免疫。

综述目的:免疫疗法已成为一种很有前景的癌症治疗方法，然而仅在特定的临床适应症中取得成功强调了对新方法的需求。最近，以单核细胞增生李斯特菌为基础的疫苗已被开发用于驱动肿瘤特异性t细胞反应。在这里，我们讨论了最近使用单核增生乳杆菌疫苗的临床前研究，影响t细胞启动的先天免疫途径，以及临床试验中的新疫苗策略。最近的发现:最近的研究表明，除了诱导抗原特异性t细胞反应，单核增生乳杆菌疫苗重塑TME。此外，几种先天免疫途径影响对单核增生乳杆菌的适应性免疫反应，调节这些途径有望增强抗肿瘤t细胞反应。摘要:先天免疫和适应性免疫对单核增生乳杆菌的相互作用尚不清楚。了解这些相互作用将有助于设计更好的抗癌疫苗和改进联合疗法的使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Clinical Microbiology Reports MICROBIOLOGY-

CiteScore

7.50

自引率

1.90%

发文量

期刊介绍： Current Clinical Microbiology Reports commissions expert reviews from leading scientists at the forefront of research in microbiology. The journal covers this broad field by dividing it into four key main areas of study: virology, bacteriology, parasitology, and mycology. Within each of the four sections, experts from around the world address important aspects of clinical microbiology such as immunology, diagnostics, therapeutics, antibiotics and antibiotic resistance, and vaccines. Some of the world’s foremost authorities in the field of microbiology serve as section editors and editorial board members. Section editors select topics for which leading researchers are invited to contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, which are highlighted in annotated reference lists. These timely reviews of the literature examine the latest scientific discoveries and controversies as they emerge and are indispensable to both researchers and clinicians. The editorial board, composed of more than 20 internationally diverse members, reviews the annual table of contents, ensures that topics address all aspects of emerging research, and where applicable suggests topics of critical importance to various countries/regions.